TNFRSF8 and neoplasm: Next, targeting the tumor immune microenvironment via CD30-targeted immunochemotherapy with brentuximab vedotin (BV) and/or an immune checkpoint inhibitor (ICPi) therapy were a considerable progress to HL therapy (Moskowitz et al., 2021; Fornecker et al., 2023; Herrera et al., 2023; Spinner et al., 2023; Alig et al., 2024).